Table 5.

Alterations in the SLE-related antibodies before and after 12 months of treatment. Values are mean (SD) unless otherwise indicated.

SLE-related Antibodies	Vitamin D Group	Placebo Group	p
Anti-dsDNA, U/ml
Baseline	55.8 (14.1)	55.6 (14.2)	0.67
% positive	86	85
12 months	32.8 (12.7)	44.8 (13.9)	0.05
% positive	67	82
Anti-Sm, U/ml
Baseline	10.79 (9.01)	10.75 (8.81)	0.66
% positive	25	24
12 months	8.21 (7.82)	9.59 (7.94)	0.05
% positive	16	22
C4 (mg/l)
Baseline	0.166 (0.091)	0.168 (0.089)	0.65
12 months	0.270 (0.071)	0.179 (0.079)	0.05
Anticardiolipin IgG, GPL IU/ml
Baseline	11.1 (2.3)	11.3 (2.5)	0.66
% positive	22	21
12 months	10.9 (2.1)	11.1 (2.0)	0.59
% positive	18	19
Anticardiolipin IgM, GPL IU/ml
Baseline	7.9 (2.4)	7.8 (2.2)	0.61
% positive	18	17
12 months	7.5 (2.1)	7.6 (2.5)	0.65
% positive	14	16